Market revenue in 2023 | USD 212.7 million |
Market revenue in 2030 | USD 341.1 million |
Growth rate | 7% (CAGR from 2023 to 2030) |
Largest segment | Stimulants |
Fastest growing segment | Non-stimulants |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Stimulants, Non-stimulants |
Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Johnson & Johnson, Lupin, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Mallinckrodt PLC Ordinary Shares - New, Vital KSK Holdings Inc, NeuroSense Therapeutics Ltd, Supernus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to attention deficit hyperactivity disorder market will help companies and investors design strategic landscapes.
Stimulants was the largest segment with a revenue share of 70.85% in 2023. Horizon Databook has segmented the China attention deficit hyperactivity disorder market based on stimulants, non-stimulants covering the revenue growth of each sub-segment from 2018 to 2030.
The Chinese population is inclined toward the use of traditional herbal medicine for the treatment of ADHD due to fewer adverse effects than pharmacologic medication. Stimulant medications available in China for the treatment of ADHD include methylphenidate and dexamphetamine.
Local companies entering into licensing agreements with foreign organizations for the production & development of novel ADHD medicines is expected to boost the market in China. For instance, in December 2021, Ark Biopharmaceutical Limited and Commave Therapeutics, SA, signed a licensing agreement to develop, manufacture, and commercialize AZSTARYS in greater China.
Tris's specially formulated, extended-release liquid and chewable ADHD medications aim to address this treatment gap, providing innovative therapeutic choices for the underserved pediatric ADHD population in China and equipping healthcare professionals with enhanced tools for effective patient care.
Horizon Databook provides a detailed overview of country-level data and insights on the China attention deficit hyperactivity disorder market , including forecasts for subscribers. This country databook contains high-level insights into China attention deficit hyperactivity disorder market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account